Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06175065 · ClinicalTrials.gov registry record · Phase 2
Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
A Phase 2 study of Acute Exacerbation of Chronic Obstructive Pulmonary Disease, sponsored by ReAlta Life Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT06175065: Active Phase 2 study of Acute Exacerbation of Chronic Obstructive Pulmonary Disease, sponsored by ReAlta Life Sciences.
NCT06175065 is a Phase 2 study of Acute Exacerbation of Chronic Obstructive Pulmonary Disease that is active but no longer recruiting, run by ReAlta Life Sciences. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06175065, a Phase 2 study of Acute Exacerbation of Chronic Obstructive Pulmonary Disease, is active but no longer recruiting, sponsored by ReAlta Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL). RLS-0071 is a novel peptide being developed for the treatment of AECOPD. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of adults with moderate exacerbations of COPD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RLS-0071
Study Locations (4)
Florida
- Site 02 - St. Petersburg
Maryland
- Site 03 - Glen Burnie
Nebraska
- Site 04 - Omaha
Pennsylvania
- Site 01 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2025-06 |
| Phase | Phase 2 |
What the registry record for NCT06175065 still lists
NCT06175065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Acute Exacerbation of Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06175065 reports a single indexed study location in Florida, Maryland, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06175065 about?
NCT06175065 is a clinical study titled "Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease". AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL). RLS-0071 is a novel peptide being developed for the treatment of AECOPD. This study is designed to evaluate the safety and tolerability of...
What is the current status of trial NCT06175065?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-01-25. Estimated completion is 2025-06.
What conditions does trial NCT06175065 study?
This clinical trial studies the following conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT06175065?
The interventions under investigation include: Placebo (DRUG), RLS-0071 (DRUG).
Who is sponsoring clinical trial NCT06175065?
This trial is sponsored by ReAlta Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06175065 being conducted?
This trial has 4 study locations across Florida, Maryland, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06175065's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI